Criterion Validation of an Open-source Wearable Physiological Sensors Device

Antoine Langevin1a, William Bégin2c, Martin Lavallière3e, Louis-David Beaulieu2d, Bob-Antoine J. Menelas3e, Sébastien Gaboury3f, Kevin Bouchard3a, Ghyslain Gagnon1h and Linda Paquette2a.

1Department of Electrical Engineering, École de Technologie Supérieure, Montreal, Canada
2Department of Health Sciences, Université du Québec, Chicoutimi, Canada
3Department of Computer Sciences and Mathematics, Université du Québec, Chicoutimi, Canada

Keywords: Open-source, Photoplethysmogram, PPG, Electrodermal Activity, EDA, Wearable Device, Sensor.

Abstract: Wearable sensors are very popular in monitoring sport performances and increasingly used in scientific research. However, several scientific and ethical issues regarding pricing, raw data accessibility, validity and commercial access to user’s data are linked with these devices. To address these limitations, an open-source device, called Emotibit, was designed through crowdfunding. The aim of this study is to evaluate the criterion validity of this new open-source device’s physiological components in resting position. To this end, heart rate (HR) and heart rate variability (HRV) via photoplethysmography (PPG) and electrodermal activity (EDA) were assessed and compared with a medical grade reference device, the FlexComp Infiniti. The Bland-Altman plot and ratio (BAR) results indicate a good validity for HR estimation with a BAR of 0.02. However, results suggest an insufficient validity for HRV, as well as EDA amplitude and number of activation events estimation. These results are comparable to other studies using PPG for HRV estimation, but the EDA components need adjustment in regard to the sensitivity of the device. We analyze the validity issues associated with open source technology, and conclude that further improvements are required to qualify its accuracy with statistical significance. This study also contributes to the wearable sensors studies by identifying and describing the many challenges associated with the democratization of access to biosensing technology.

1 INTRODUCTION

Wearable sensors are becoming omnipresent, especially in monitoring sport performances. The global wearable sensor market was estimated at 7.44B$ USD in 2017, more than 28% above the 2015 prediction for year 2018 which was thought to reach 5.88B$ USD (Casselman et al., 2017). According to Business Wire, this market was expected to grow by more than 32% between 2018 and 2022. The global wearable market reaching 69B$ USD in 2020 (81B$ USD by the end of 2021). The growth of remote work combined with an increased interest in health monitoring during the COVID-19 is thought to have brought forward this already booming market (Rimol, 2021).

Wearable sensors have also rapidly gained attention amongst the scientific community. For example, a search about “wearable sensor” in PubMed reveals that the number of published scientific articles has increased from 38 in 2007 to 546 in 2017, an average annual growth rate of 30%. In sports, wearables are used to assess the heart rate (HR) and heart rate variability (HRV) associated with exertion in a training situation (e.g. Fitbit, Polar, Apple watch, Garmin, Hexoskin, and many others), and wearable inertial measurement units (IMU) are used to assess the level of physical activity and the movement of the body during the exercise, for example the number of steps taken in a day (e.g. Fitbit and Polar) or the characteristics of jumps during aerial maneuvers in board sports (e.g. PiqRossignol, Woosport, and Trace). The majority of wearables...
combine both physiological sensors and IMU to some extent for physical activity, HR and HRV (e.g. Fitbit and Polar).

Unfortunately, several hurdles curtail the usefulness of many of these devices for scientific investigations. First, most commercially available wearable sensors do not give access to the raw (unfiltered) data. Secondly, there is an ethical issue with the fact that most companies use anonymized recorded data from wearables for commercial purposes via their web platform, with no possibility for scientists to avoid the use of data from participants by companies (Allhoff and Henschke, 2018; Arias et al., 2015; Mittelstadt, 2017). Thirdly, the reliability and validity of the data recorded is often not available or suitable for research purposes (Peake et al., 2018). Fourthly, available medical grade devices used for physiological data collection (e.g. Biopac or FlexComp Infiniti of Thought Technology Ltd) are often cumbersome, expensive (over 5k$) and do not allow for field and sports research.

We propose that one of the solutions lies in the creation and validation of an open-source wearable multi-sensors having internal storage capabilities. This sensor should be designed to be worn on various body parts, thus allowing access to raw data and global knowledge about the electronic circuit and code of the device’s firmware and software. As much as the open access movement recently redefined the scientific publication process and access (Tennant et al., 2016), we argue that there is value in a similar process with research on advanced technologies, which could also be open sourced for the improvement of scientific research and democratization of access to valid physiological and inertial sensors data (Bernal et al., 2021).

To this end, a new partnership between Université du Québec à Chicoutimi, Ecole de Technologie Supérieure and Connected Future Labs has enabled the creation of a new open-source wearable device that allows research-grade acquisition of movement and physiological data: the Emotibit¹. This device allows data collection that is fully accessible and private to the user.

2 WEARABLE MULTI-SENSOR DEVICE

The Emotibit open-source device analyzed in this work is a wearable Arduino compatible module used to capture physiological and inertial movement data.

The wearable device consists of 6 sensors related to human physiological data: 1) 3-wavelength photopletysmogram (PPG) based on the MAX30101; 2) 9-axis IMU with accelerometers (ACC) and gyroscopes (GYR) based on BMI160 and magnetometer based on the BMM150; 3) temperature based on the far infrared sensor MLX90632; 4) humidity with a second temperature sensor based on the Si7013; and 6) electrodermal activity (EDA) based on a custom electronic circuit. Table 1 provides a complete list of sensors supported by the device. All data are recorded on an SD card for further offline analysis, but a wireless data streaming option is also possible for live analysis and evaluation of signals’ quality. More information can be found on the Emotibit webpage² and in the GitHub repository² of the device.

In order to respect the writing rate of the SD card while maintaining accurate collection of all data, different sampling rates are used for the sensors. Motions and changes in blood volume are recorded at the sampling rate of 25 Hz, while physiological data with a lower rate of change are recorded at a sampling rate of 15 Hz for the EDA and at a sampling rate of 7.5 Hz for temperature and humidity.

The availability of all these sensors on a small device makes it wearable in many places on the body and allows the participant to practice numerous activities without any discomfort or interference to movements due to the device. Figure 1 shows images of the Emotibit module bottom layer and top layer with component layout.

3 METHOD

The aim of this work is the criterion validity assessment of the wearable Emotibit device by comparing its data with gold standard measures of cardiovascular activity (CVA) and EDA evaluations (Bassett Jr et al., 2012). The study uses the standardized protocol proposed by van Lier et al. (2019) for the analysis of signals from wearable technologies. The analysis focus on two variable levels: signal and parameter levels. The signal level is a comparison made on the raw data. It assesses the ability of the device to extract the same raw signals as the reference device (RD). The RD used in this study is the FlexComp Infiniti biofeedback device by Thought Technology Ltd³. On the other hand, the parameter level is important to determine

¹www.emotibit.com

²https://github.com/EmotibIt

³https://thoughttechnology.com/flexcomp-system-with-biograph-infiniti-software-t7555m/
Table 1: Physiological and IMU sensors description on Emotibit.

<table>
<thead>
<tr>
<th>Function</th>
<th>Data Type</th>
<th>Description</th>
<th>Sampling Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>PPG</td>
<td>PI, PG, PR</td>
<td>Infrared, green, red lights</td>
<td>25 Hz</td>
</tr>
<tr>
<td>Motion</td>
<td>AX, AY, AZ</td>
<td>Accelerometer (3 axis)</td>
<td>25 Hz</td>
</tr>
<tr>
<td></td>
<td>GX, GY, GZ</td>
<td>Gyroscope (3 axis)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>MX, MY, MZ</td>
<td>Magnetometer (3 axis)</td>
<td></td>
</tr>
<tr>
<td>Temperature &amp; Humidity</td>
<td>T0, H0</td>
<td>Temperature, Humidity</td>
<td>7.5 Hz</td>
</tr>
<tr>
<td>EDA</td>
<td>EA, EL, ER</td>
<td>EDA, high and low variations</td>
<td>15 Hz</td>
</tr>
</tbody>
</table>

3.1 Reference Device

The FlexComp Infiniti biofeedback is a medical grade device. It measures EDA, HR, and HRV through two pairs of Ag/AgCl electrodes. The sampling rate of all measures from the RD is 256 Hz. The HR and HRV are calculated from the electrocardiogram (ECG) signal measured by electrodes placed on a chest strap, while EDA is measured using two electrodes usually attached to the fingers. The RD is connected to a computer via a USB connection and communicates with the Biograph Infiniti software that records the data in a database. Once the collection is completed, the raw data can be extracted in CSV format for further analysis.

3.2 Participants

A total of 24 participants were selected through a self-assessment health interview. Participants were informed that they would participate in a validity assessment study for the Emotibit wearable device. A protocol approved by the local ethics committee (602.317.04) was put in place to ensure the safety of the subjects. Informed consent was obtained from all individual participants included in the study. Of all subjects, 9 were females and 15 males, all between the ages of 21 and 42 years old (26.5 ± 6). The participants were selected from the general population, without known cardiac problems, with an average body mass index of 23.5 ± 3.4 kg/m².

3.3 Sensors Positioning

During the whole experiment session, the Emotibit device is worn on the thumb fingertip with the PPG sensors facing the underside of the thumb. Both Ag/AgCl electrodes for the Emotibit EDA are attached to two different fingers, which is the most responsive location to stimuli (Kasos et al., 2020). For comparison purposes, the three ECG electrodes of the FlexComp device are located on both collar bones and on V5, and two additional electrodes from the FlexComp are attached to the same two fingers as the Emotibit electrodes to compare the EDA measurements. Figure 2 shows a participant’s hand with all sensors attached (ECG electrodes are not displayed on the figure).

3.4 Test Procedure

The experiment counts in two sessions of 10 minutes each in a laboratory environment. Both monitoring sessions are performed in a resting situation where the participant is asked to sit on a chair for 10 minutes and asked to move as little as possible, with hands resting on the table. At the beginning and end of each session, the participant is asked to press a push button connected to the RD three times. Pulses from the push button aligned with those observed on the accelerometer of the Emotibit device allow...
the synchronization of timestamps between devices. After these instructions, participants are asked to read and sign an informed consent. Then, all sensors are attached to the participant as described in Section 3.3 and data collection begins.

4 DATA ANALYSIS

Before performing both signal and parameter level analysis, we conducted a data quality assessment of the EDA and CVA signals collected from Emotibit and RD.

4.1 Data Quality Assessment

During preliminary analysis of Emotibit data, following the end of the data collection, we detected a strong attenuation in the PPG sensor measurements and a presence of significant noise in the sensor measurements when the battery charge drops below a certain threshold. As a result, several recordings had to be ignored for the CVA and the EDA evaluation due to the significant deterioration of the signal. A data quality assessment protocol proposed by van Lier et al. (2019) and summarized in this section is used to remove invalid data.

4.1.1 EDA

Data quality assessment of the EDA signals is conducted by visual inspection of skin conductance (SC) data to identify measurement issues as recommended by Boucsein (2012). Two researchers inspected the signals for irregularities that could be due to misplacement of the sensors or errors during recording. From the 48 resting measurements, 14 (29%) were rejected, including four related to the failure of the RD FlexComp. A total of 34 sessions with EDA data were included in this study for the signal and parameters comparison.

4.1.2 CVA

As PPG is prone to motion artifacts and optical interference, we calculate a signal quality index (SQI) for the PPG signal from Emotibit. Proposed by Orphanidou et al. (2014), the goal of the SQI is to provide an objective measure of the degree of signal corruption.

The SQI is divided in three steps and is calculated on individual 10-second segments. First, we detect PPG pulse-peaks in each segment using an adaptive peak detection (Van Gent et al., 2018) provided by the library Heartpy (van Gent et al., 2019). The second step is to compare the output of the PPG pulse-peaks detector with a set of three physiological rules. If one of the following rules is not satisfied, the segment is classified as “bad”:

1) **Rule 1:** The HR extrapolated from the 10-s segment must be between 30 and 180 beats per minutes (bpm). This is the physiological probable range of HR for the adult participants in this study.
2) **Rule 2:** The maximum acceptable gap between successive PPG pulse-peaks is 3 seconds. This rule ensures no more than one beat is missed.
3) **Rule 3:** The ratio of the maximum beat-to-beat interval to the minimum beat-to-beat interval within the sample should be less than 2.2. Within a 10-second segment, the HR is not expected to change by more than 10%, and we consider the possibility of a single missed beat.

If all the three rules are satisfied, the final step is to calculate the average correlation coefficient between each PPG-pulse peak within the 10-s segment. The approach proposed by Orphanidou et al. (2014) is as follows:

1) For each sample, the median beat-to-beat interval is calculated using all the detected PPG-pulse peaks.
2) Individual PPG-pulse waves are extracted by taking a window of width equal to the median beat-to-beat interval centered on each PPG-pulse peak.
3) The average PPG pulse-wave template is obtained by taking the mean of all PPG-pulse waves of the sample. The correlation coefficient of each individual PPG-pulse wave with the PPG pulse-wave template is then calculated.
4) The average correlation coefficient is finally obtained by averaging all correlation coefficients over the whole PPG sample.

The 10-s segment is classified as “bad”, if the average correlation coefficient is less than 0.86 (Orphanidou et al., 2014). If more than 50% of the segments in a 10-minute session are classified as “bad”, the session is discarded for the rest of the analysis.

Over the 48 sessions recorded, only six (12.5%) were discarded. On the 42 remaining sessions, 91% of all 10-s segments satisfied all rules and obtained an average correlation coefficient higher than 0.86. Most rejected segments were containing a gap larger than 3 seconds, where more than one PPG pulse peaks were not detected by the algorithm caused by strong signal attenuation or noisy segments.
4.2 Signal Comparison: Cross Correlation Function

The first comparison, at the signal level, verifies the validity of the Emotibit by comparing the signals measured by the wearable device with those of the RD. This analysis is relevant for researchers interested in using the Emotibit’s raw signal in their work.

The signal-level analysis is done by cross correlation between signals. The cross correlation is a measure widely used to determine the similarity between two time-series (Chen et al., 2015). To eliminate problems that could be related to the synchronization between the Emotibit and the RD signals, we compute the cross correlation relatively shifting the signals by ±8 sampling intervals (time lag from -8 to +8 sampling intervals) and we keep only the highest correlation among them.

In this work, we perform the signal comparison only for the EDA measurements. Due to the different sensing technology of PPG vs ECG to measure HR, the signal waveforms are significantly different as shown in Figure 3. Therefore, no analysis was performed to qualify the similarity between those two signals. Instead, CVA parameters were extracted for both signals, and then compared.

4.2.1 EDA

The following steps proposed by van Lier et al. (2019) are used to determine the cross correlation between the EDA signals:

1. **Resample Data to the Same Frequency.** Measurements from the RD are sampling at 256 Hz, whereas EDA measures from Emotibit are sampling at 15 Hz. We down sample the reference EDA to 15 Hz.

2. **Normalize and Detrend Data.** We normalize and detrend data to make both signals comparable and to make the time series stationary.

3. **Determine Cross Correlation at Multiple Time Lags.** We determine cross correlation between signals with time lags from -8 to +8 samples, meaning lags between -0.53 s to 0.53 s with a sampling rate of 15 Hz.

4. **Find Highest Cross Correlation and Plot Histogram.** Using the highest cross correlation, we finally plot a histogram to illustrate an overview of signal level comparison for the EDA.

![Figure 3: Comparison between PPG and ECG signals with examples of PP and RR intervals.](image)

4.3 Parameters Comparison: Bland-Altman Plot

The Bland-Altman plot is an analysis used to compare two measurements of the same variable. It describes the agreement between two quantitative measurements of a particular parameter using a visual representation. It helps identify structural biases that might be present in the data. In this work, we use the Bland-Altman plot to evaluate three parameters extracted from the EDA signals and three parameters from the CVA signals. For each parameter, we add boundaries (also known as limits of agreement) to the Bland-Altman plot set to ±10% of the biological plausible value. These boundaries are the limit of the acceptable error (van Lier et al., 2019).

4.3.1 EDA

The Bland-Altman plots for the parameters comparison of the EDA data are obtained by the following steps proposed by van Lier et al. (2019):

1. **Step 1.**
   Same as step 1 in Section 4.2.1.

2. **Analyze the Data.** The EDA data are analyzed with the Matlab-based Ledalab software (Benedek and Kaernbach, 2010). The phasic activity is extracted using trough-to-peak (TTP) analysis with a threshold of 0.01 uS (Boucsein, 2012). We keep the default settings of the software for the filtering and smoothing preprocessing.

3. **Retrieve the EDA Parameters.** Three parameters from the EDA data are evaluated with a Bland-Altman plot:
Mean Skin Conductance Level (SCL). The SCL is calculated by averaging the EDA data over the complete 10-minute session. The biological plausible values for SCL is between 0 and 16 µS (Braithwaite et al., 2013). The boundaries of the Bland-Altman plot are then ±1.6 µS.

Number of Skin Conductance Responses (SCRs). The number of SCRs over the entire session is determined by the TTP analysis. The total number of SCRs is then converted to a number of SCRs per minute. Biological plausible values for the numbers of SCRs per minute is on average 1-3 per minute according to Braithwaite et al. (2013), but it can reach 20-25 SCRs per minute during high arousal (Boucsein, 2012). The boundaries of the Bland-Altman plot are therefore ± 2.5 SCRs.

SCRs Total Amplitude (S-AMPL). The amplitude of an SCR is the difference between the SC values of its peak and the previous trough. The amplitudes of all SCRs are summed to obtain the total amplitude, which is then converted to total amplitude per minute. Biological plausible values for amplitudes are between 0 and 3 µS according to Braithwaite et al. (2013) and with 20-25 SCRs per minute the range of total amplitudes is between 0 and 0.3 × 20 = 6 µS when using the most conservative values. The boundaries of the Bland-Altman plot are therefore ± 0.6 µS.

4. Create a Bland-Altman Plot. Create the Bland-Altman plot where the abscissa (x-axis) is the mean of the two measurements and the ordinate (y-axis) is the difference between the two values. Additionally, plot boundaries of the acceptable error and the 95% confidence interval of the difference. Finally, calculate the amount of data outside the acceptable boundaries.

5. Calculate the Bland-Altman Ratio. In addition to the Bland-Altman plot, we calculate the Bland-Altman ratio (BAr) (Schäfer and Vagedes, 2013) to assess the quality of agreement for each parameter. The BAr is given by:

$$\text{BAr} = \frac{1.96 \cdot SD}{Apm}$$

where SD is the standard deviation of the difference between the two values, Apm is the average of the pairwise means and 1.96 is used to create a 95% confidence interval around the SD. BAr<0.01 is considered as an excellent agreement, values between 0.01 and 0.1 are considered as a good agreement, values between 0.1 and 0.2 as a moderate agreement, and values >0.2 are defined as insufficient agreement.

4.3.2 CVA

The Bland-Altman plots for the parameters comparison of the CVA data are obtained by the following steps proposed by van Lier et al. (2019):

1. Down and Up Sample the Data to the Same Frequency. Downsampel the reference ECG data to 100 Hz and upsample Emotibit PPG data to 100 Hz using a linear interpolation.

2. Analyze the Filtered Data. The raw ECG data is filtered with a notch filter to remove noise without disturbing the QRS complexes. The raw PPG data is filtered with a band-pass filter between 0.7 Hz and 3.5 Hz. The filtered data is then analyzed using the library Heartpy (van Gent et al., 2019). The peaks of R-waves and P-waves are detected using an adaptive peak detection (Van Gent et al., 2018). The duration between successive peaks are calculated to produce RR/PP intervals as shown in Figure 3. Intervals shorter than 0.33 s and longer than 2 s are removed since the biological plausible range of HR is between 30 and 180 bpm, as indicated in steps 1 and 2 of the SQI assessment.
3. Retrieve the CVA Parameters. Three parameters from the ECG and PPG data are evaluated with a Bland-Altman plot:

**Mean RR/PP Interval.** The mean RR and PP interval is the mean of all valid intervals over the 10-minute session. The mean RR and PP interval is then converted in instantaneous HR. According to van Lier et al. (2019) the boundaries of the Bland-Altman plot are ±5 bpm.

**SD RR/PP Interval.** The standard deviation (SD) over the RR and PP intervals. According to O’Neal et al. (2016) the biological plausible values are between 0 and 0.56. The boundaries of the Bland-Altman are ±0.06.

**RMSSD.** The root mean square of the successive RR/PP interval differences (RMSSD) reflecting the beat-to-beat variance in HR. The RMSSD is defined by:

$$\text{RMSSD} = \sqrt{\frac{1}{N-1} \sum_{i=1}^{N-1} (RR_{i+1} - RR_i)^2}$$

(2)

Biological plausible values are between 0 and 0.71 s (O’Neal et al., 2016), the boundaries of the Bland-Altman plot are ±0.07 s.

4. Step 4. and 5. Same as step 4 and 5 for EDA in Section 4.3.1.

The data and code used to create results in this paper is available in our "OS-VAL-PPG-EDA" repository.4

5 RESULTS

This section describes results of the signal and parameters comparison between the Emotibit device and the RD.

5.1 Signal Comparison: Cross Correlation Function

5.1.1 EDA

The results of the EDA signal comparison correspond to the maximum value of the cross correlation for each 10-minute session between –8 and +8 lags in time. Figure 4 illustrates the results by a histogram representing the distribution of the cross correlation obtained for each session. We note that the majority of the sessions, i.e. 29 out of 36, obtain a cross correlation higher than 0.8, considered as a very high correlation (Evans, 1996). The average cross correlation over all sessions corresponds to 0.87.

Figure 5 shows the SC measurements for the reference and the Emotibit devices with a high cross correlation (0.99). We can clearly distinguish any fluctuations in the measurements for both devices. We also notice that the SCL is similar between the two devices, which is not the case for the session with low cross correlation shown in Figure 6. For the latter, the signal measured by the Emotibit is about 5 μS lower and suffers from strong attenuation making SCRs imperceptible.

5.2 Parameters Comparison: Bland-Altman Plot

5.2.1 EDA

The results of the parameters comparison for the EDA data are shown in Figure 7 by three Bland-Altman plots: (a) the mean SCL, (b) the number of SCRs on average per minute, and (c) the total amplitude of SCRs on average per minute.

We observe, in Figure 7 (a), that the average SCL is underestimated by the Emotibit device with an average difference of -1.18 μS. Although the differences in SCL increase with respect to SCL values, no proportional bias emerges from the results. Of the 34 sessions analyzed, we count only six sessions that obtained an SCL higher than the reference SCL. In addition, we note that only 67% of the sessions are within ±1.6 μS, with 11 sessions below the lower acceptable boundary. Finally, BAr = 1.01 is significantly higher than the moderate agreement of 0.2 and therefore considered as insufficient agreement.

Although there is a degree of imprecision in the SCL measured by the Emotibit device, the number of

4https://github.com/AntoineLan/OS-VAL-PPG-EDA
Figure 6: SC measurements for a 10-minute session with low cross correlation (0.42).

SRCs detected is comparable to the numbers of SCRs detected by the RD. As shown in Figure 7 (b), the number of SCRs detected by the Emotibit is slightly higher, with an average difference of 0.42 SCRs per minute, or approximately 4 more SCRs detected per 10-minute session. However, the mean difference in the number of detected SCRs between the Emotibit and the RD stands within established boundaries for 94% of all 10-minute sessions. However, since we are not in a high arousal situation, the difference is high compared to the average noSCRs and yields a BAr = -0.51 suggesting insufficient agreement for this parameter.

Combining the evaluation of the SCL and the detected SCRs, Figure 7 (c) shows the results of the comparison between the Emotibit and the RD regarding the total amplitude of SCRs per minute. We first note that there is a large group of points around the 0 µS error. However, about eleven 10-minute sessions achieve an S-AMPL difference lower than -0.34 µS. As suggested by the results in Figure 7 (a), the SCL measured by the Emotibit is lower than the SCL measured by the RD, which also affects the total amplitude of SCRs. Although most of the SCRs detected by the Emotibit device have a lower amplitude than the RD, 79% of the 10-minute sessions lie inside the ±0.6 µS boundaries. The BAr indicates an insufficient agreement with a value equal to 1.91.

5.2.2 CVA

The results of the parameters comparison for the CVA data are shown in Figure 7 by three Bland-Altman plots: (d) the mean HR, (e) the SD over the RR and PP intervals, and (f) the RMSSD.

In Figure 7 (d), we note that the mean HR estimated from the Emotibit PPG signal is accurate with an average difference of -0.02±1.7 bpm compared to the mean HR measured from the ECG signal. The results of all 10-minute sessions lie inside the boundaries of +/- 5 bpm. In addition, Figure 8 shows an example of HR calculated at 2-seconds intervals for a 10-minute session. The session is divided into windows of 8 seconds with a stride of 2 seconds using a sliding window technique. We notice a strong correlation between the HR calculated from the PPG signal of the Emotibit and the HR calculated from the ECG signal of the RD supported by the BAr = 0.02 indicating a good agreement.

The results of the mean standard deviation of the interbeat interval are shown in Figure 7 (e). As observed for the mean HR, the results of the Emotibit compared to the RD are comparable with a mean difference of 7.8 ms and a 95% confidence interval of ±15.23 ms. All 10-minute sessions lie inside the acceptable boundaries of ±60 ms. The comparison is considered as a moderate agreement with a BAr = 0.18.

The RMSSD calculated from the Emotibit PPG data is on average 26.76 ms higher than the RMSSD calculated from the ECG data of the RD. The RMSSD calculated from the PPG measurements of the Emotibit sampled at 25 Hz are more affected by a low sampling rate than previous parameters (Fujita and Suzuki, 2019). Although 90% of the sessions lie inside the acceptable boundaries, the BAr = 0.63 indicates an insufficient agreement.

6 DISCUSSION

The aim of this study was the criterion validity assessment of the wearable Emotibit device, following the standardized protocol proposed by van Lier et al. (2019).

The signal-level comparison for the EDA indicates a very high correlation between the Emotibit and the reference measurements. This finding is in line with that of Kasos et al. (2020) who found very high correlation when EDA electrodes are attached to the fingers. Although the majority of the data lies inside the acceptable boundaries set to 10% of the biological plausible range (van Lier et al., 2019), the boundaries for the noSCRs and S-AMPL parameters are determined to account for high arousal situations which is not the case in this study with an average noSCRs per minute of 5.1. Thus, the results of the signal-level comparison are promising, but the cross-correlation measure cannot detect a mean bias between the two measurements. Therefore, the SCL comparison results indicate a problem with the amplitude of the measured SC that affects all other
Figure 7: Bland-Altman plots for the parameters comparison of the EDA data on the left: (a) the mean SCL, (b) the number of SCRs per minute, and (c) the S-AMPL per minute, and for the CVA data on the right: (d) the mean HR, (e) the SD of the RR/PP intervals, and (f) the RMSSD. Each dot represents one 10-minute session. The x-axis corresponds to the average of the two measures, and the y-axis is the difference between the two measures. Both green lines represent the acceptable boundaries. The orange lines are the 95% confidence interval limits found and the blue line represents the mean value. The percentage of sessions which lie inside the acceptable boundaries is given at the bottom of each plot, whereas the BAr is given at the top right of each plot.
extracted parameters. In the lights of these results, we do not recommend the Alpha version of the Emotibit device for scientific purposes to determine accurate SCL.

The results obtained from the parameters comparison of the CVA data show the validity of the Emotibit to determine the HR from the PPG signal with a good agreement (Chen et al., 2015). However, the PPG sampling rate of 25 Hz impacts the results for the SD RR/PP interval and RMSSD parameters. The SD RR/PP interval parameter is validated with moderate agreement, whereas the RMSSD obtains insufficient agreement to be validated. This is in line with Schäfer and Vagedes (2013) and Béres et al. (2019) who reported that the reliability of HRV parameters is affected by the sampling rate and the RMSSD is the most susceptible due to its beat-to-beat-weighted sensitivity. It should be noted that measurements were performed in the resting position and the Emotibit was placed on the fingertip, which helps to detect blood volume changes. Using the Emotibit on the wrist and during activities could reduce the performance of the PPG sensor due to motion artifacts.

The Emotibit is constantly evolving, and a Beta version is soon to be released, providing several adjustments and performance improvements to the wearable device. However, during the monitoring sessions of the current experiment only the Alpha version was available and thus was the subject of this criterion validity assessment.

7 CONCLUSION

Open source wearable device solutions are important to democratize access to these technologies and to ethically ensure control over our personal data and that of research project participants. However, in order to be accessible to the largest number of people, open-source devices must remain affordable, which adds constraints to the technologies used and therefore affects their performance.

In the light of this criterion validity assessment of the wearable Emotibit device, we conclude that the measurement of EDA still needs to be improved, especially to adjust sensitivity of the SCL. The Emotibit device is accurate to estimate the HR by using the PPG sensors. However, the results for the HRV parameters could be improved by increasing the PPG sampling frequency.

The versatility of the Emotibit device allows it to be used in many conditions and environments, such as indoor and outdoor activities. Considering these results, the Emotibit is an interesting wearable device for sports applications and also for physiological feedback for art and video game applications. However, further experiments should be done to validate the device in other situations i.e. when performing activities. In this regard, two new experimental studies using this wearable device have already been initiated in the field of sports, more specifically for snowboarding and trampoline practice. The set of physiological and spatio-temporal sensors will allow us to analyze the experiments from several angles, both at the psychosocial and technical levels. We already expect that the movements associated with the practice of these activities will reduce the quality of the PPG signals (Kim and Yoo, 2006). Thus, part of the experimental study will involve the use of IMU to determine HR in order to reduce the influence of motion on the performance of the wearable device (Mashhadi et al., 2015; Lee et al., 2018).

Finally, an additional criterion validity assessment will be conducted using the new Beta version of the Emotibit. For this purpose, a modified version of Bruce’s protocol (Bruce, 1971) will be used, in which the participant will be asked to alternate between walking and running on a treadmill to simulate activity conditions in a controlled environment.

REFERENCES


